Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model
- PMID: 32193102
- DOI: 10.1016/j.intimp.2020.106394
Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model
Abstract
Allergic rhinitis (AR) is a complex IgE-mediated nasal allergic and inflammatory disease. Nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) is essential in the process of allergic and inflammatory responses. MCC950 is a selective NLRP3 inhibitor. However, its role and mechanism in AR remains undetermined. The present study aimed to explore the effect and mechanism of MCC950 on an ovalbumin (OVA) induced mouse model of AR. The AR BALB/c mice were constructed using OVA and administrated intranasally with MCC950. Concentrations of OVA-specific IgE, histamines and leukotrienes C4 (LTC4) in serum, and OVA-specific IgE, ECP, IFN-γ, IL-4, IL-5, IL-13, IL-1β and IL-18 in nasal lavage fluid (NLF) were assayed by enzyme-linked immunosorbent assay (ELISA). Inflammatory cells were counted in NLF. HE and PAS staing were used for evaluating eosinophils and goblet cells. Immunohistochemistry (IHC) staining were employed to evaluate immunolabeling of NLRP3, Caspase-1, ASC, IL-1β and IL-18 in nasal mucosas of mice. Real-time PCR was conducted to assay NLRP3, Caspase-1, ASC, IL-1β and IL-18 mRNA levels. In vitro studies, western blotting, real-time PCR and ELISA were performed to evaluate the effects and mechanisms of OVA and NLRP3 inhibitor MCC950 on spleen mononuclear cells. We found significant downregulation of sneezing, nasal rubbing, inflammatory cytokines, inflammatory cells and NLRP3, Caspase-1, ASC, IL-1β and IL-18 expression in MCC950 treated mice compared with untreated AR mice. In spleen mononuclear cells culture and stimulation experiment, NLRP3, Caspase-1, ASC, IL-1β and IL-18 levels were upregulated by OVA but inhibited by MCC950. In conclusion, MCC950 could effectively exert its ameliorative effect in murine AR by inhibiting NLRP3 and leads to reduction of Caspase-1, ASC, IL-1β and IL-18, resulting in the attenuation of the allergic and inflammatory responses.
Keywords: ASC; Allergic rhinitis; Caspase-1; MCC950; NLRP3.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.Int Immunopharmacol. 2019 Sep;74:105575. doi: 10.1016/j.intimp.2019.04.022. Epub 2019 Jul 9. Int Immunopharmacol. 2019. PMID: 31299609
-
MicroRNA-133b Ameliorates Allergic Inflammation and Symptom in Murine Model of Allergic Rhinitis by Targeting Nlrp3.Cell Physiol Biochem. 2017;42(3):901-912. doi: 10.1159/000478645. Epub 2017 Jun 26. Cell Physiol Biochem. 2017. PMID: 28662502
-
Immunomodulation in allergic rhinitis: Insights from Th2 cells and NLRP3/IL-18 pathway.Cell Biochem Funct. 2024 Apr;42(3):e3997. doi: 10.1002/cbf.3997. Cell Biochem Funct. 2024. PMID: 38555506
-
Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.Inflammation. 2020 Feb;43(1):17-23. doi: 10.1007/s10753-019-01098-8. Inflammation. 2020. PMID: 31646445 Review.
-
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome.Eur J Pharmacol. 2022 Aug 5;928:175091. doi: 10.1016/j.ejphar.2022.175091. Epub 2022 Jun 14. Eur J Pharmacol. 2022. PMID: 35714692 Review.
Cited by
-
Unraveling the role of NLRP3 inflammasome in allergic inflammation: implications for novel therapies.Front Immunol. 2024 Jul 26;15:1435892. doi: 10.3389/fimmu.2024.1435892. eCollection 2024. Front Immunol. 2024. PMID: 39131161 Free PMC article. Review.
-
Influences of miR-378a-3p on the Pathogenesis of Allergic Rhinitis via GzmB-Mediated Inflammatory Reaction.Evid Based Complement Alternat Med. 2022 Aug 29;2022:5926834. doi: 10.1155/2022/5926834. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 36072399 Free PMC article.
-
The NLRP3 inflammasome as a new target in respiratory disorders treatment.Front Immunol. 2022 Sep 20;13:1006654. doi: 10.3389/fimmu.2022.1006654. eCollection 2022. Front Immunol. 2022. PMID: 36203607 Free PMC article. Review.
-
Pneumococcal Δpep27 Immunization Attenuates TLRs and NLRP3 Expression and Relieves Murine Ovalbumin-Induced Allergic Rhinitis.J Microbiol Biotechnol. 2022 Jun 28;32(6):709-717. doi: 10.4014/jmb.2203.03006. Epub 2022 Apr 18. J Microbiol Biotechnol. 2022. PMID: 35484967 Free PMC article.
-
Platelet-Activating Factor Disrupts the Nasal Epithelial Barrier Independently of the Platelet-Activating Factor Receptor Pathway.Allergy Asthma Immunol Res. 2025 Mar;17(2):212-225. doi: 10.4168/aair.2025.17.2.212. Allergy Asthma Immunol Res. 2025. PMID: 40204506 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous